US headquartered Rakuten Medical, which has recently established a subsidiary in India, is now exploring regulatory pathways to commercialize treatments based on the Alluminox platform in India, beginning with head and neck cancer.
This therapy area uses non-thermal red light to target cancer cells in the head and neck region after the patient has been administered with an injectable drug about a day back. The therapy is already approved in Japan, and Rakuten is working to get it approved by the USFDA. The company’s co-CEO Mickey Mikitan met top cancer specialists in India recently.
Abhijit Bhatia, Chief Strategy Officer, India